



# Handbook on the EMA and OGYÉI Guidances on Clinical Trials during the COVID-19 pandemic

KPMG Legal Tóásó Law Firm

Budapest, March 24, 2020.

# Guidance of the European Medicines Agency (EMA)

The purpose of the **EMA** Guidance on Clinical Trials during the COVID-19 pandemic, issued on March 20, 2020, is to establish **general, EU-level** recommendations to those who participate in clinical trials. However, it also aims to **draw companies' attention** to the need to **comply with any specific national legislation and guidance** that may take priority over these recommendations.

## Main recommendations to follow in connection with the ongoing trials:

- Conversion of physical visits into **phone or video visits**
- A temporary halt of the trial at **some or all** trial sites
- **Suspension or slowing down** of recruitment of new trial participants
- **Extension** of the duration of the trial and/or **postponement** of certain trials

Furthermore, according to the Guidance, in the case of ongoing clinical trials **on treatments for COVID-19**, it may be necessary to develop **alternative procedures** to obtain **informed consent**, as it is likely that the physical consent cannot be acquired.

In addition, it is necessary to consider the commencement or continuation of activities if the participants are at **any potential risk of COVID-19**.





# Guidance of the National Institute of Pharmacy and Nutrition (OGYÉI)

On the basis of OGYÉI's latest Guidance on the continuity of clinical trials, dated March 24, 2020, a **thorough risk assessment** of ongoing trials **shall be conducted**. Furthermore, **measures to improve patient safety and validity of data shall be imposed**.

According to the OGYÉI Guidance, it should be considered to **stop the patient enrollment process** during this period. OGYÉI also draws attention to the fact that the **use of electronic means for obtaining informed consent** and **providing patient information (package leaflet)** is **not permitted** in accordance with the provisions of the relevant legislation, even in the current state of danger.

## Authorisation

- It is sufficient to send requests for clinical trials and substantial amendments using OGYÉI's online portal.
- Substantial amendment of the clinical trial, to ensure the continued involvement of the participant, can be issued as an "urgent safety measure".

## Visits

- Conversion of physical visits into phone visits must be taken into consideration.
- In case it is not feasible for a trial site to continue the trial, it shall be suspended.

## Monitoring

- Alternative proportionate mechanisms of oversight shall be preferred to reduce on-site monitoring.
- Providing the representative of the Sponsor with copies of medical records or remote control to electronic medical records is not allowed.

## Distribution of IMP

- Re-distribution of Investigational Medicinal Products between sites, providing patients with supply for longer periods than originally planned during on-site visits, or delivery of the IMP directly to the patient's home may arise.

Should you have any questions, feel free to contact us.

---



**Contacts:**

**dr. Bálint Tóásó MSc LL.M (Vienna)**

Partner, Head of Legal Services

T: +36 30 663 6245

E: balint.toaso@kpmg.hu

**dr. Ildikó Csák**

Director, Attorney-at-Law

T: +36 70 978 934

E: ildiko.csak@kpmg.hu

**dr. Fanni Márkus**

Associate

T: +36 70 333 1502

E: fanni.markus@kpmg.hu

The information contained herein are only for information purposes and shall not apply to any circumstances of any specific legal or natural persons or other entities without legal personality. Though KPMG intends to provide accurate and timely information, however, shall not undertake any responsibility for the present or future effectiveness of any information set out herein. KPMG does not undertake responsibility for damages arising from such activities which were based on the usage of the information set out herein and which lacks full analysis and advisory activity of KPMG.

KPMG name, KPMG logo is the registered trademark of KPMG International Cooperative ("KPMG International").

© 2019 KPMG Legal Tóásó Law Firm, a Hungarian law firm registered in the Budapest Bar Association and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved.

